Search research articles
Contact Us
Filters
Showing results (1-10 of 254) with videos related to
Page
of 26
Sort By:
Expert Opinion on Pharmacotherapy
|
October 13, 2007
Pharmacogenetics of acute lymphoblastic leukemia treatment response
Lea Cunningham, Richard Aplenc
British Journal of Haematology
|
May 15, 2004
Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia
Richard Aplenc, Beverly Lange
Current Opinion in Pediatrics
|
December 10, 2019
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy
Caitlin W Elgarten, Richard Aplenc
Current Hematologic Malignancy Reports
|
May 11, 2019
Disparities in Survival and Health Outcomes in Childhood Leukemia
Lena E Winestone, Richard Aplenc
Current Hematologic Malignancy Reports
|
March 31, 2021
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery
Tamara P Miller, Richard Aplenc
Pediatric Blood & Cancer
|
November 13, 2010
Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005
Kelsey A Johnson, Richard Aplenc, Rochelle Bagatell
Frontiers in Oncology
|
March 28, 2014
Molecular therapeutic approaches for pediatric acute myeloid leukemia
Sarah K Tasian, Jessica A Pollard, Richard Aplenc
Leukemia & Lymphoma
|
July 16, 2005
No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia
Janez Jazbec, Lidija Kitanovski, Richard Aplenc, et al.
Pediatric Blood & Cancer
|
October 2, 2012
The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists
Tammy I Kang, Kari Hexem, Russell Localio, et al.
Pediatric Blood & Cancer
|
January 11, 2013
Epidemiology of childhood acute myeloid leukemia
Susan E Puumala, Julie A Ross, Richard Aplenc, et al.
Page
of 26
Search research articles
Search
Showing results (1-10 of 254) with videos related to
Sort By:
Page
of 26
Expert Opinion on Pharmacotherapy
|
October 13, 2007
Pharmacogenetics of acute lymphoblastic leukemia treatment response
Lea Cunningham, Richard Aplenc
British Journal of Haematology
|
May 15, 2004
Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia
Richard Aplenc, Beverly Lange
Current Opinion in Pediatrics
|
December 10, 2019
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy
Caitlin W Elgarten, Richard Aplenc
Current Hematologic Malignancy Reports
|
May 11, 2019
Disparities in Survival and Health Outcomes in Childhood Leukemia
Lena E Winestone, Richard Aplenc
Current Hematologic Malignancy Reports
|
March 31, 2021
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery
Tamara P Miller, Richard Aplenc
Pediatric Blood & Cancer
|
November 13, 2010
Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005
Kelsey A Johnson, Richard Aplenc, Rochelle Bagatell
Frontiers in Oncology
|
March 28, 2014
Molecular therapeutic approaches for pediatric acute myeloid leukemia
Sarah K Tasian, Jessica A Pollard, Richard Aplenc
Leukemia & Lymphoma
|
July 16, 2005
No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia
Janez Jazbec, Lidija Kitanovski, Richard Aplenc, et al.
Pediatric Blood & Cancer
|
October 2, 2012
The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists
Tammy I Kang, Kari Hexem, Russell Localio, et al.
Pediatric Blood & Cancer
|
January 11, 2013
Epidemiology of childhood acute myeloid leukemia
Susan E Puumala, Julie A Ross, Richard Aplenc, et al.
Page
of 26